"Positive Zotatifin Data Supports An Opportunity In Breast Cancer" - Cantor Fitzgerald Bullish on eFFECTOR Therapeutics (EFTR) With Overweight Rating, $50 Price Target Jun 6, 2022 06:27AM
Cantor Fitzgerald Reiterates eFFECTOR Therapeutics (EFTR) at Overweight, $50 PT, "Company's Pipeline Remains Underappreciated", Expect Advancements to Move Stock Higher Mar 16, 2022 07:12PM
UPDATE: Cantor Fitzgerald Starts eFFECTOR Therapeutics, Inc. (EFTR) at Overweight Sep 13, 2021 06:03AM
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies Aug 25, 2021 07:18PM
eFFECTOR Therapeutics and Locust Walk Acquisition (LWAC) Announce Merger Agreement May 27, 2021 08:02AM


May 27, 2021 08:00AM eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies